Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology

May 11, 2017 Group News
evs-msc

The Cell Factory expands its patent portfolio on extracellular vesicles biologic drugs in China.

Esperite’s (Euronext: ESP) biotech company The Cell Factory has obtained the patent for use of extracellular vesicles (EVs) in treatment of acute and chronic inflammatory and autoimmune diseases in China. This allows The Cell Factory entering into one of the largest markets of advanced therapeutics with its disruptive technology of the extracellular vesicles products replacing allogenic MSCs therapies. The Cell Factory will be presenting its EVs products: CF-MEV-107 for treatment of Crohn’s disease and CF-MEV-117 for treatment of drug resistant epilepsy during ChinaBio Partnering Forum 2017 in Zhuhai, China from May 31-June 1, 2017.

Zutphen, The Netherlands – 11 May 2017

read more

Esperite (ESP) leads international consortium for clinical translation of extracellular vesicles use in various therapies

September 30, 2016 Group News
evs-msc

Extracellular vesicles (EVs) disruptive technology targets unmet needs in neuroinflammatory diseases at lower costs than allogenic stem cell therapies.

Esperite’s business unit The Cell Factory develops EVs-based therapeutics in treatment of drug-resistant epilepsy in children jointly with Bambino Gesù Children’s Hospital, Mario Negri Institute for Pharmacological Research and the Women’s and Children’s Health Department of the University of Padua.

Zutphen, The Netherlands – 30 September 2016

read more